Navigation Links
NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Date:11/15/2011

SAN FRANCISCO, Nov. 15, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today presented positive preclinical data for NKTR-102, a next-generation topoisomerase I inhibitor, at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer being held in San Francisco, California.  The preclinical data demonstrates that NKTR-102 administered in combination with pegylated liposomal doxorubicin (PLD) in vivo has strong synergistic anti-cancer properties exhibiting a 100% complete response rate with no tumor re-growth in over 90% of animals.  In addition, the study showed that there was no additive toxicity when combining NKTR-102 with PLD in a preclinical model of ovarian cancer.

"Results from these nonclinical studies of NKTR-102 combined with PLD and as a single agent are highly compelling," said Robert Medve, M.D., Chief Medical Officer of Nektar Therapeutics. "In the models of platinum-resistant ovarian cancer, NKTR-102 showed synergistic anti-tumor activity with PLD.  These preclinical data support the future exploration of NKTR-102 in combination with PLD in platinum-resistant ovarian cancer."  

The data presented at the 2011 AACR-NCI-EORTC meeting show that in an in vivo model of platinum-resistant human ovarian cancer, a single-dose of single-agent NKTR-102 resulted in a 100 percent complete response rate and a delay in tumor growth of up to 38 days at the highest dose.  In the same model, multiple doses of single-agent PLD achieved only one partial response and a delay in tumor growth of up to only 24 days at its highest dose.  NKTR-102 administered in combination with PLD showed synergistic anti-tumor activity with a 100 percent complete response rate and no tumor re-growth for 93% of the animals within a 69-day observation period.  

NKTR-102 and PLD Nonclinical DataThese data were pres
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
2. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
3. Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
4. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
5. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
6. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
7. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
8. Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
9. Prototype demonstrates success of advanced new energy technology
10. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
11. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, ... Family purchased a DNA test to unravel ... with a lifetime of memories, sharing, and closeness. In ... DNA genuinely brought the family closer together. , ... genetic history and prior to taking the genetic ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) today announced ... scheduled to present at the Rodman & Renshaw,10th Annual ... Tuesday, November 11th, 2008 at 2:50 p.m. Eastern Time ... 2008 at the,Palace Hotel in New York., The ...
... Driven by the emergence of innovative technologies ... and proteomics, world market for drug discovery ... by 2012. Despite the heavy costs involved ... pharmaceutical research and development are reaching new ...
... of Wisconsin-Madison engineers and physicists have developed a method ... that could lay the foundation for faster flexible electronics. ... electronic devices. Silicon thin films could be the basis ... inducing strain into the silicon increases device speed, yet ...
Cached Biology Technology:Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 2Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 3Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 4Stretching silicon: A new method to measure how strain affects semiconductors 2
(Date:7/11/2014)... BostonThe American Society for Bone and Mineral Research awarded ... of Medicine (BUSM), with the 2014 Louis V. Avioli ... at BUSM, is internationally known for revolutionizing the understanding ... , The award honors a member of the ... fundamental contributions to bone and mineral basic research. It ...
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... When researchers at the National Institute of Standards ... do their work more effectively, they often prove ... Such was the case recently for M. Lorna ... in the growing specialization of glycomics. Glycomics is ... called glycans that are attached to proteins and ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... Since the 1960s, psychiatrists have been hunting for substances ... high levels to produce the symptoms associated with schizophrenia. ... might be related to the hallucinogens phencyclidine (PCP) or ... of psychotic symptoms in schizophrenia. This "auto-intoxication" hypothesis led ...
... March 14, 2013 In the largest ever ... genetics company, identified 20 new genetic associations for myopia, ... in the study, which was specific to individuals of ... data and survey responses from more than 50,000 23andMe ...
... to feed, some whales throw their jaws wide and engulf ... along with their mouths agape (ram or skim feeding), yet ... whales, mouths to filter nutrition from the ocean: baleen. Alexander ... how the hairy substance actually traps morsels of food. ,The ...
Cached Biology News:The mysterious GRIN3A and the cause of schizophrenia 223andMe identifies multiple genetic factors impacting development of nearsightedness 2Whale's streaming baleen tangles to trap food 2
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Fetal Calf Serum Replacement (Bistec) serum...
...
Biology Products: